Inhibitors of bruton's tyrosine kinase

Abstract

Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

1 . A compound of Formula (D) having the structure: 
       
         
           
           
               
               
           
         
       
       wherein:
 L a  is S; 
 Ar is a substituted or unsubstituted heteroaryl; 
 Y is an optionally substituted group selected from alkyl; 
 Z is NHS(═O) x , where x is 1 or 2; 
 R 7  and R 8  are independently selected from unsubstituted C 2 -C 6 heterocycloalkyl 
 R 6  is C 1 -C 4 alkyl(C 2 -C 8 heterocycloalkyl); and 
 pharmaceutically acceptable salts thereof. 
 
     
     
         2 - 21 . (canceled)